Jose Tinajero

15PUBLICATIONS
27CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)HaematologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Psychological methodology, design and analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Nov 20, 2025
FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience.

Jose Tinajero, Dat Ngo, Brian Lee

|Sep 10, 2025
The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden.

Jose Tinajero, Kim Nguyen, Dat Ngo

|Sep 01, 2025
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia.

Hoda Pourhassan, Jose Tinajero, Huiyan Ma

|Jun 10, 2025
The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission.

Jose Tinajero, Dat Ngo, Maria Motta

|May 21, 2025
Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old.

Purav Mehta, Dat Ngo, Jose Tinajero

|Jan 17, 2025
TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL.

Ibrahim Aldoss, Shanpeng Li, Jianying Zhang

Pageof 3

Frequent Collaborators

9 joint publications

Dat Ngo

8 joint publications

Hoda Pourhassan

7 joint publications

Paul Koller

5 joint publications

Vaibhav Agrawal